HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT01959035

Once-Monthly Aripiprazole Safety and Effectiveness in Schizophrenia

About this titleRead the official source — NCT01959035
Medication studyAges 18–60United States
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.

Listed locations
San DiegoSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateOctober 2013
Recruitment status
Completed
Enrollment listed in the registry
88
Sponsor
H. Lundbeck A/S
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
From 18 Years to 60 Years
Official registry ID
NCT01959035
Official title
Show the full official title

Interventional, Open-label, Flexible-dose Extension Study of Aripiprazole Once-monthly in Patients With Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

San Diego

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is H. Lundbeck A/S.

Did this study involve medication?

Yes. The study involved medication, including Aripiprazole once-monthly.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies